Respiratory Syncytial Virus (RSV) is an enveloped RNA virus and the second leading cause of death in infants under one year old. RSV presents significant vaccine development challenges. Despite approvals of RSV vaccines for older adults and pregnant women, recent attempts to develop paediatric RSV vaccines have failed, leaving a critical treatment gap. Inactivated vaccines using chemical methods damage critical protein-based antigens required for protective immune responses. Ionising radiation offers a promising alternative, as it can inactivate viral RNA while preserving key protective antigens, though this approach remains understudied. This project investigates whether ionising radiation can inactivate RSV and develop effective vaccine candidates. RSV samples were exposed to varying radiation doses to determine optimal inactivation conditions, verified through viral titration. Vaccine candidates were characterized using RT-qPCR, confocal microscopy, and ELISAs. RSV was also irradiated with ROS scavengers to evaluate preservation of pre-Fusion (F) protein, which has neutralisation-sensitive antigenic sites absent on post-Fusion conformations and induces more potent neutralising antibodies required for protective immunity. Results demonstrated that RSV is effectively inactivated at 16kGy with preserved F protein expression and conformation. Confocal microscopy confirmed that inactivated RSV retained cellular attachment and entry capacity, indicating maintained F protein conformation. ROS scavenger treatment increased pre-Fusion protein preservation, suggesting potentially enhanced immunological protection. These findings establish electron radiation as an effective RSV inactivation method suitable for vaccine development. ROS scavenger co-treatment offers a pathway to optimize protective antigen preservation and improve vaccine efficacy. Further work will focus on in vivo studies of these vaccine candidates.